Rasonque Offers a New Treatment Option for Advanced Pancreatic Cancer

For people facing advanced pancreatic cancer, a new treatment can mean another opportunity to control the disease and more time with the people they love. Rasonque, the brand name for daraxonrasib, has shown a substantial survival benefit compared with standard chemotherapy in a major clinical trial.

The medicine is taken by mouth once daily and targets RAS, a protein family involved in cancer growth. The U.S. Food and Drug Administration approved Rasonque on August 26, 2026.

The latest development comes from Europe. On October 15, the European Medicines Agency’s human medicines committee recommended authorising Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment. That recommendation is an important regulatory step; the European Commission must still make the authorisation decision.

For American patients, the immediate question is whether Rasonque fits their diagnosis, previous treatment, and current health. European and U.S. regulatory decisions follow separate processes.

Why this development matters

Pancreatic cancer is frequently diagnosed at a stage when surgery cannot completely remove it. Once cancer has spread to distant parts of the body, treatment decisions generally focus on controlling the disease, extending life, and managing symptoms.

Chemotherapy remains an important treatment. But a person whose disease progresses after an initial regimen may have limited options, and the physical burden of further treatment can be substantial. The National Cancer Institute’s pancreatic cancer treatment overview describes how chemotherapy, targeted therapies, clinical trials, and symptom management fit into care.

Rasonque adds another treatment approach for eligible patients. Its strongest comparative evidence comes from people whose metastatic disease had already progressed after treatment.

How Rasonque works

RAS proteins help regulate cell growth and survival. In pancreatic adenocarcinoma, mutations can leave these proteins continually active, sending growth signals that cancer cells depend on.

Daraxonrasib works with another protein, cyclophilin A, to form a complex that attaches to RAS and blocks its activity. This can interrupt the signals supporting cancer growth.

The EMA announcement explains the mechanism in the context of the new recommendation. Rasonque is a targeted cancer medicine, with a mechanism distinct from conventional cytotoxic chemotherapy.

What the clinical trial found

The pivotal study, RASolute 302, was an international, randomised phase 3 trial involving 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma.

Researchers assigned 248 patients to daraxonrasib and 252 to chemotherapy selected by their physician. The trial was open label, meaning patients and treating clinicians knew which treatment was given. It was funded by Revolution Medicines, the medicine’s developer.

The findings were published in the New England Journal of Medicine. The published study abstract is available through PubMed.

In the overall study population, the original analysis reported:

Measure Rasonque Standard chemotherapy

Median overall survival 13.2 months 6.7 months Median progression-free survival 7.2 months 3.6 months Objective response rate 30% 11%

These figures are reported in the FDA’s clinical approval summary.

Overall survival measures how long patients live. Progression-free survival measures time before the cancer worsens or the patient dies. Objective response measures the proportion whose tumours shrink enough to meet predefined criteria; it does not mean those patients were cured.

The original overall-survival comparison corresponded to a hazard ratio of 0.40. This is often described as a 60% reduction in the hazard of death during follow-up. It should not be interpreted as a 60% cure rate or a promise that every patient will live 60% longer.

Why the EMA announcement says 12.4 months

Readers comparing announcements may notice two different survival figures for Rasonque: 13.2 months in the original analysis and 12.4 months in the EMA announcement.

The manufacturer’s October 15 explanation of the results distinguishes the prespecified primary analysis from a subsequent ad hoc survival analysis. The original analysis reported 13.2 months versus 6.7 months; the later analysis reported 12.4 months versus 6.7 months.

The EMA announcement uses the later estimate, based on survival data collected through June 15, 2026. Median survival estimates can change as follow-up matures. These are separate analyses of the same trial, rather than results from two different trials.

Both analyses support a substantial survival improvement. The later comparison represents a difference of 5.7 months between the group medians.

What survival statistics mean for a family

A median is the point at which an estimated half of a study group remains alive. Some people live longer and some live for less time.

The National Cancer Institute defines median overall survival as a measure used to assess treatment effectiveness. It is a group statistic, not a personal deadline.

The difference between two medians also cannot tell a particular patient exactly how much additional time a medicine will provide. A useful oncology discussion should consider expected benefit alongside treatment burden, current symptoms, daily functioning, and the patient’s own priorities.

Who may be eligible

The U.S. indication covers adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy or who are not candidates for multiagent systemic therapy.

The European recommendation covers adults with metastatic pancreatic adenocarcinoma after at least one previous systemic therapy.

The diagnosis and stage matter. These indications should not be expanded into a claim that Rasonque is approved for every pancreatic tumour or every stage of pancreatic cancer.

About 92% of trial participants had a RAS G12 mutation. The study also included smaller groups with other RAS findings or no identified mutation. The U.S. indication has no mutation-specific restriction, but the small size of some subgroups matters when interpreting their evidence.

Patients should still ask about molecular testing. The National Cancer Institute explains that tumour testing can help identify other targeted treatment or immunotherapy options.

Taking a cancer medicine at home still requires close care

The FDA-approved prescribing information lists a recommended Rasonque dose of 300 mg once daily, with or without food. The treating clinician determines the appropriate dose and any adjustments.

Treatment at home still requires a plan for taking the medicine consistently, monitoring symptoms, reviewing other medications, and contacting the oncology team.

The trial results also need context. Participants had already received treatment and had an ECOG performance status of 0 or 1, meaning they were fully active or restricted mainly in strenuous activity. Outcomes may differ in people who are substantially more unwell or have different treatment histories.

These details appear in the FDA-approved prescribing information.

Side effects deserve a clear discussion

Common side effects include rash, diarrhea, mouth inflammation or sores, nausea, fatigue, vomiting, abdominal pain, swelling, reduced appetite, and bleeding.

The medicine also carries warnings about potentially serious skin reactions, gastrointestinal perforation, lung inflammation, and harm to a developing fetus. Drug interactions can require changes to treatment, so the oncology team needs a complete list of prescription medicines, nonprescription products, vitamins, and supplements.

Severe abdominal pain or new or worsening breathing symptoms require immediate contact with the healthcare team. Patients should also report new or worsening diarrhea, mouth sores, and skin reactions promptly.

The published trial reported grade 3 or higher adverse events in 61.8% of patients receiving daraxonrasib and 69.6% receiving chemotherapy. Those figures include adverse events occurring during treatment, regardless of whether investigators attributed them to the medicine. They show why a targeted oral therapy still requires careful monitoring.

Access and insurance questions

According to the manufacturer’s patient support information, Rasonque prescriptions are handled through specialty pharmacies, with the oncology office and pharmacy coordinating delivery.

Patients and caregivers should ask the prescribing office and health plan:

• Is Rasonque covered under my current benefits?
• What documentation or prior authorisation is required?
• Which specialty pharmacy must fill the prescription?
• What will I pay, and what assistance might I qualify for?
• Who should I contact if approval or delivery is delayed?

The manufacturer’s (ON)Path program offers access advocates and several support options with eligibility requirements. Patients can ask their care team to help review those requirements. A support program listing should not be taken as a guarantee of free medicine or a specific out-of-pocket cost.

Research is testing earlier treatment

Researchers are also studying whether Rasonque can help earlier in the course of metastatic disease.

In September 2026, Revolution Medicines reported an FDA Breakthrough Therapy Designation for Rasonque combined with gemcitabine and nab-paclitaxel in previously untreated metastatic pancreatic adenocarcinoma. The combination is being studied in the phase 3 RASolute 303 trial.

As the company’s research announcement states, that combination remains investigational. A designation intended to accelerate development does not establish approval for the combination.

Patients interested in a trial should ask their oncologist whether an appropriate study is available and how participation compares with currently approved treatment.

Supportive care remains part of treatment

A new anticancer medicine does not address every need that comes with advanced pancreatic cancer. Pain, poor appetite, fatigue, emotional distress, and caregiver strain all deserve attention.

The National Cancer Institute’s explanation of palliative care describes support that can begin during active cancer treatment. It can include symptom management, nutrition support, emotional and spiritual care, and help for caregivers.

Families can ask the oncology team to identify one clear contact for questions and help coordinate specialists, pharmacy services, and supportive care. Keeping an updated medication list and bringing written questions to appointments can make those conversations more useful.

For someone with metastatic pancreatic adenocarcinoma, Rasonque is a reason to revisit available treatment options with an oncologist. The evidence supports longer survival and delayed progression in the studied population. The next decision is personal: how that evidence fits the patient’s health, goals, and care plan.

This article provides general health information. Treatment decisions should be made with a qualified oncology professional who knows the patient’s medical history.